Pleconaril Treatment of Enterovirus and Rhinovirus Infections

Harley A. Rotbart, MD, University of Colorado Health Sciences Center, Denver


Infect Med. 2000;17(7) 

In This Article

Abstract and Introduction

The enteroviruses and rhinoviruses are, together, the most common causes of infections in the developed world and the most common reasons for prescribing antibiotics. These pathogens are responsible for a wide spectrum of human disease, ranging from the common cold and nonspecific febrile illnesses to myocarditis, meningitis and, in certain patient populations, potentially life-threatening infections. Pleconaril, a first-of-its-kind viral capsid-inhibitor compound, has potent in vitro and in vivo activity against enteroviruses and rhinoviruses. Clinical trials to date have shown that pleconaril provides clinical benefit for patients with enteroviral meningitis, viral respiratory infections, and potentially life-threatening enteroviral infections in at-risk patient populations. Pleconaril also has a very favorable safety profile.

The enteroviruses (EVs) and rhinoviruses (RVs) are ubiquitous human pathogens, responsible for a wide array of clinical syndromes (Table 1). Recently, a novel antiviral compound, pleconaril, has shown efficacy against these viruses in several important diseases. This article will review the virology and clinical significance of the EVs and RVs and summarize the preclinical and clinical experiences with pleconaril to date.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: